A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
Kato A, Miyoshi N, Ohtsuru T, Sakai D, Hasegawa J, Nakata K, Imasato M, Kato T, Ikenaga M, Kudo T, Tei M, Kagawa Y, Uemura M, Takahashi H, Satoh T, Mori M, Mizushima T, Yamamoto H, Murata K, Doki Y, Eguchi H.
Kato A, et al. Among authors: imasato m.
Anticancer Res. 2022 Apr;42(4):1859-1865. doi: 10.21873/anticanres.15662.
Anticancer Res. 2022.
PMID: 35347004
Clinical Trial.